Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study

Jeremy D. Shapiro, Subotheni Thavaneswaran, Craig R. Underhill, Kristy P. Robledo, Christos S. Karapetis, Fiona L. Day, Louise M. Nott, Michael Jefford, Lorraine A. Chantrill, Nick Pavlakis, Niall C. Tebbutt, Timothy J. Price, Mustafa Khasraw, Guy A. Van Hazel, Paul M. Waring, Sabine Tejpar, John Simes, Val J. Gebski, Jayesh Desai, Eva Segelov

    Research output: Contribution to journalArticle

    6 Citations (Scopus)

    Abstract

    Most unresectable metastatic colon cancer remains incurable, with a median survival of less than 3 years. Molecularly targeted therapies have recently been developed; in particular, monoclonal antibodies against the epidermal growth factor receptor, which are efficacious in 40% to 60% of chemotherapy-resistant patients with wild-type KRAS. This study shows that cetuximab plus irinotecan, compared with cetuximab alone, increases the response rate and delays progression in irinotecan-resistant RAS wild-type colorectal cancer. Background: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation (ICECREAM) study assessed the efficacy of cetuximab monotherapy compared with cetuximab combined with chemotherapy for quadruple wild-type (KRAS, NRAS, BRAF, or P13KCA exon 20) metastatic colorectal cancer. Patients and Methods: Patients were enrolled in an open-label, multicenter, phase II trial and randomly assigned to cetuximab 400 mg/m2, then 250 mg/m2 cetuximab weekly, with or without irinotecan 180 mg/m2 every 2 weeks. The primary endpoint was 6-month progression-free survival; secondary endpoints were response rate, overall survival, toxicity, and quality of life. Results: From 2012 to 2016, 48 patients were recruited. Two were ineligible, and 2 were not evaluable for response. Characteristics were balanced, except gender (male, 62% vs. 72%) and primary sidedness (left, 95% vs. 68%). For cetuximab compared with cetuximab-irinotecan, progression-free survival was 14% versus 41% (hazard ratio, 0.39; 95% confidence interval, 0.20-0.78; P =.008); response rate was 10% (2 partial responses) versus 38% (1 complete, 8 partial); P =.04. Grade 3 to 4 toxicities were less with cetuximab monotherapy (23% vs. 50%); global and specific quality of life scores did not differ. Conclusion: In comparison with cetuximab alone, cetuximab plus irinotecan increases the response rate and delays progression in irinotecan-resistant RAS wild-type colorectal cancer. This echoes data from molecularly unselected patients.

    Original languageEnglish
    Pages (from-to)313-319
    Number of pages7
    JournalClinical Colorectal Cancer
    Volume17
    Issue number4
    DOIs
    Publication statusPublished - 1 Dec 2018

    Keywords

    • Cetuximab
    • Chemotherapy colon cancer
    • Irinotecan
    • RAS

    Fingerprint Dive into the research topics of 'Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study'. Together they form a unique fingerprint.

  • Cite this

    Shapiro, J. D., Thavaneswaran, S., Underhill, C. R., Robledo, K. P., Karapetis, C. S., Day, F. L., Nott, L. M., Jefford, M., Chantrill, L. A., Pavlakis, N., Tebbutt, N. C., Price, T. J., Khasraw, M., Van Hazel, G. A., Waring, P. M., Tejpar, S., Simes, J., Gebski, V. J., Desai, J., & Segelov, E. (2018). Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study. Clinical Colorectal Cancer, 17(4), 313-319. https://doi.org/10.1016/j.clcc.2018.06.002